Peter A. Thompson - Net Worth and Insider Trading

Peter A. Thompson Net Worth

The estimated net worth of Peter A. Thompson is at least $1.2 Billion dollars as of 2025-07-20. Peter A. Thompson is the Director, 10% Owner of Synthorx Inc and owns about 5,316,355 shares of Synthorx Inc (THOR) stock worth over $361 Million. Peter A. Thompson is the Director, 10% Owner of Prevail Therapeutics Inc and owns about 13,822,463 shares of Prevail Therapeutics Inc (PRVL) stock worth over $318 Million. Peter A. Thompson is also the Director, 10% Owner of Edgewise Therapeutics Inc and owns about 15,252,867 shares of Edgewise Therapeutics Inc (EWTX) stock worth over $207 Million. Besides these, Peter A. Thompson also holds ARS Pharmaceuticals Inc (SPRY) , Sionna Therapeutics Inc (SION) , Silverback Therapeutics Inc (SBTX) , Corvus Pharmaceuticals Inc (CRVS) , Decibel Therapeutics Inc (DBTX) , Alpine Immune Sciences Inc (ALPN) , Janux Therapeutics Inc (JANX) , Adaptimmune Therapeutics PLC (ADAP) , PMV Pharmaceuticals Inc (PMVP) . Details can be seen in Peter A. Thompson's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Peter A. Thompson has not made any transactions after 2025-06-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Peter A. Thompson

Peter A. Thompson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Peter A. Thompson owns 16 companies in total, including PMV Pharmaceuticals Inc (PMVP) , Prevail Therapeutics Inc (PRVL) , and Corvus Pharmaceuticals Inc (CRVS) among others .

Click here to see the complete history of Peter A. Thompson’s form 4 insider trades.

Insider Ownership Summary of Peter A. Thompson

Ticker	Company	Transaction Date	Type of Owner
PMVP	PMV Pharmaceuticals Inc	2020-09-25	director & 10 percent owner
PRVL	Prevail Therapeutics Inc	2020-06-17	director & 10 percent owner
CRVS	Corvus Pharmaceuticals Inc	2025-06-27	director & 10 percent owner
		2020-01-23	director & 10 percent owner
		2023-12-28	director
		2018-09-13	director
		2018-06-06	director
		2016-11-29	director & 10 percent owner
		2015-07-15	director
		2013-07-12	director
		2012-05-08	director
		2021-02-17	director & 10 percent owner
		2020-12-08	director & 10 percent owner
		2025-04-03	director & 10 percent owner
		2021-12-29	director
		2024-08-26	director

Peter A. Thompson Latest Holdings Summary

Peter A. Thompson currently owns a total of 12 stocks. Among these stocks, Peter A. Thompson owns 5,316,355 shares of Synthorx Inc (THOR) as of December 11, 2018, with a value of $361 Million and a weighting of 29.44%. Peter A. Thompson owns 13,822,463 shares of Prevail Therapeutics Inc (PRVL) as of June 24, 2019, with a value of $318 Million and a weighting of 25.89%. Peter A. Thompson also owns 15,252,867 shares of Edgewise Therapeutics Inc (EWTX) as of April 3, 2025, with a value of $207 Million and a weighting of 16.82%. The other 9 stocks ARS Pharmaceuticals Inc (SPRY) , Sionna Therapeutics Inc (SION) , Silverback Therapeutics Inc (SBTX) , Corvus Pharmaceuticals Inc (CRVS) , Decibel Therapeutics Inc (DBTX) , Alpine Immune Sciences Inc (ALPN) , Janux Therapeutics Inc (JANX) , Adaptimmune Therapeutics PLC (ADAP) , PMV Pharmaceuticals Inc (PMVP) have a combined weighting of 27.85% among all his current holdings.

Latest Holdings of Peter A. Thompson

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
THOR	Synthorx Inc	2018-12-11	5,316,355	67.99	361,458,976
PRVL	Prevail Therapeutics Inc	2019-06-24	13,822,463	23.00	317,916,649
EWTX	Edgewise Therapeutics Inc	2025-04-03	15,252,867	13.54	206,523,819
SPRY	ARS Pharmaceuticals Inc	2024-08-26	8,288,510	17.92	148,530,099
SION	Sionna Therapeutics Inc	2025-02-10	3,704,959	16.74	62,021,014
SBTX	Silverback Therapeutics Inc	2020-12-08	8,740,888	5.87	51,309,013
CRVS	Corvus Pharmaceuticals Inc	2025-06-27	7,165,006	4.27	30,558,751
DBTX	Decibel Therapeutics Inc	2021-02-17	4,945,192	4.91	24,280,893
ALPN	Alpine Immune Sciences Inc	2023-12-28	264,315	64.97	17,172,546
JANX	Janux Therapeutics Inc	2021-12-29	231,098	26.40	6,100,987
ADAP	Adaptimmune Therapeutics PLC	2018-06-06	4,901,310	0.28	1,369,916
PMVP	PMV Pharmaceuticals Inc	2020-09-25	475,000	1.33	631,750

Holding Weightings of Peter A. Thompson

Peter A. Thompson Form 4 Trading Tracker

According to the SEC Form 4 filings, Peter A. Thompson has made a total of 0 transactions in Synthorx Inc (THOR) over the past 5 years. The most-recent trade in Synthorx Inc is the acquisition of 1,363,636 shares on December 11, 2018, which cost Peter A. Thompson around $15 Million.

According to the SEC Form 4 filings, Peter A. Thompson has made a total of 0 transactions in Prevail Therapeutics Inc (PRVL) over the past 5 years. The most-recent trade in Prevail Therapeutics Inc is the acquisition of 882,352 shares on June 24, 2019, which cost Peter A. Thompson around $15 Million.

According to the SEC Form 4 filings, Peter A. Thompson has made a total of 5 transactions in Edgewise Therapeutics Inc (EWTX) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Edgewise Therapeutics Inc is the acquisition of 496,771 shares on April 3, 2025, which cost Peter A. Thompson around $10 Million.

More details on Peter A. Thompson's insider transactions can be found in the Insider Trading History of Peter A. Thompson table.

Insider Trading History of Peter A. Thompson

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Peter A. Thompson Trading Performance

GuruFocus tracks the stock performance after each of Peter A. Thompson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Peter A. Thompson is 4.94%. GuruFocus also compares Peter A. Thompson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Peter A. Thompson within 3 months outperforms 14 times out of 28 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Peter A. Thompson's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Peter A. Thompson

Average Return

Average return per transaction

Outperforming Transactions

8 out of 26 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	0.15
Relative Return to S&P 500(%)	-0.82

Peter A. Thompson Ownership Network

Ownership Network List of Peter A. Thompson

No Data

Ownership Network Relation of Peter A. Thompson

Peter A. Thompson Owned Company Details

What does PMV Pharmaceuticals Inc do?

Who are the key executives at PMV Pharmaceuticals Inc?

Peter A. Thompson is the director & 10 percent owner of PMV Pharmaceuticals Inc. Other key executives at PMV Pharmaceuticals Inc include director & President and CEO David Henry Mack , SVP & Regulatory Affairs and QA Deepika Jalota , and General Counsel & COO Robert Ticktin .

PMV Pharmaceuticals Inc (PMVP) Insider Trades Summary

Over the past 18 months, Peter A. Thompson made no insider transaction in PMV Pharmaceuticals Inc (PMVP). Other recent insider transactions involving PMV Pharmaceuticals Inc (PMVP) include a net sale of 40,283 shares made by Deepika Jalota , a net sale of 31,140 shares made by Michael Carulli , and a net sale of 58,411 shares made by David Henry Mack .

In summary, during the past 3 months, insiders sold 142,876 shares of PMV Pharmaceuticals Inc (PMVP) in total and bought 0 shares, with a net sale of 142,876 shares. During the past 18 months, 152,985 shares of PMV Pharmaceuticals Inc (PMVP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 152,985 shares.

PMV Pharmaceuticals Inc (PMVP)'s detailed insider trading history can be found in Insider Trading Tracker table.

PMV Pharmaceuticals Inc Insider Transactions

No Available Data

What does Prevail Therapeutics Inc do?

Who are the key executives at Prevail Therapeutics Inc?

Peter A. Thompson is the director & 10 percent owner of Prevail Therapeutics Inc. Other key executives at Prevail Therapeutics Inc include director & 10 percent owner Carl L Gordon , General Counsel Kira M. Schwartz , and Chief Development Officer Franz Hefti .

Prevail Therapeutics Inc (PRVL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Prevail Therapeutics Inc (PRVL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prevail Therapeutics Inc (PRVL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Prevail Therapeutics Inc (PRVL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prevail Therapeutics Inc Insider Transactions

No Available Data

What does Corvus Pharmaceuticals Inc do?

Who are the key executives at Corvus Pharmaceuticals Inc?

Peter A. Thompson is the director & 10 percent owner of Corvus Pharmaceuticals Inc. Other key executives at Corvus Pharmaceuticals Inc include director & President and CEO Miller Richard A Md , See Remarks William Benton Jones , and Chief Financial Officer Leiv Lea .

Corvus Pharmaceuticals Inc (CRVS) Insider Trades Summary

Over the past 18 months, Peter A. Thompson made 1 insider transaction in Corvus Pharmaceuticals Inc (CRVS) with a net sale of 1,176,332. Other recent insider transactions involving Corvus Pharmaceuticals Inc (CRVS) include a net sale of 1,176,332 shares made by Orbimed Advisors Llc , a net purchase of 577,634 shares made by Miller Richard A Md , and a net purchase of 20,000 shares made by William Benton Jones .

In summary, during the past 3 months, insiders sold 2,352,664 shares of Corvus Pharmaceuticals Inc (CRVS) in total and bought 0 shares, with a net sale of 2,352,664 shares. During the past 18 months, 2,352,664 shares of Corvus Pharmaceuticals Inc (CRVS) were sold and 597,634 shares were bought by its insiders, resulting in a net sale of 1,755,030 shares.

Corvus Pharmaceuticals Inc (CRVS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corvus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Synthorx Inc do?

Who are the key executives at Synthorx Inc?

Peter A. Thompson is the director & 10 percent owner of Synthorx Inc. Other key executives at Synthorx Inc include 10 percent owner Ra Capital Healthcare Fund Lp , 10 percent owner Ra Capital Management, L.p. , and director & 10 percent owner Peter Kolchinsky .

Synthorx Inc (THOR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Synthorx Inc (THOR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Synthorx Inc (THOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Synthorx Inc (THOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Synthorx Inc Insider Transactions

No Available Data

What does Alpine Immune Sciences Inc do?

Who are the key executives at Alpine Immune Sciences Inc?

Peter A. Thompson is the director of Alpine Immune Sciences Inc. Other key executives at Alpine Immune Sciences Inc include Senior VP and CFO James Paul Rickey , director & Executive Chairman and CEO Mitchell Gold , and director & 10 percent owner Xiangmin Cui .

Alpine Immune Sciences Inc (ALPN) Insider Trades Summary

Over the past 18 months, Peter A. Thompson made no insider transaction in Alpine Immune Sciences Inc (ALPN). Other recent insider transactions involving Alpine Immune Sciences Inc (ALPN) include a net sale of 118,000 shares made by James Paul Rickey , and a net sale of 19 shares made by James N Topper .

In summary, during the past 3 months, insiders sold 0 shares of Alpine Immune Sciences Inc (ALPN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 118,019 shares of Alpine Immune Sciences Inc (ALPN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 118,019 shares.

Alpine Immune Sciences Inc (ALPN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alpine Immune Sciences Inc Insider Transactions

No Available Data

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Peter A. Thompson is the director of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Principia Biopharma Inc Insider Transactions

No Available Data

What does Adaptimmune Therapeutics PLC do?

Who are the key executives at Adaptimmune Therapeutics PLC?

Peter A. Thompson is the director of Adaptimmune Therapeutics PLC. Other key executives at Adaptimmune Therapeutics PLC include Chief Medical Officer Elliot Norry , Chief Operating Officer Bertrand William C Jr , and Chief Patient Supply Officer John Lunger .

Adaptimmune Therapeutics PLC (ADAP) Insider Trades Summary

Over the past 18 months, Peter A. Thompson made no insider transaction in Adaptimmune Therapeutics PLC (ADAP). Other recent insider transactions involving Adaptimmune Therapeutics PLC (ADAP) include a net sale of 90,170 shares made by Adrian Rawcliffe , a net sale of 37,522 shares made by Cintia Piccina , and a net sale of 27,779 shares made by Elliot Norry .

In summary, during the past 3 months, insiders sold 0 shares of Adaptimmune Therapeutics PLC (ADAP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 205,723 shares of Adaptimmune Therapeutics PLC (ADAP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 205,723 shares.

Adaptimmune Therapeutics PLC (ADAP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adaptimmune Therapeutics PLC Insider Transactions

No Available Data

What does Response Biomedical Corp do?

Who are the key executives at Response Biomedical Corp?

Peter A. Thompson is the director & 10 percent owner of Response Biomedical Corp. Other key executives at Response Biomedical Corp include director & 10 percent owner Orbimed Advisors Llc , director & 10 percent owner Samuel D Isaly , and director & 10 percent owner Orbimed Capital Gp Iii Llc .

Response Biomedical Corp (RPBIF) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Response Biomedical Corp (RPBIF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Response Biomedical Corp (RPBIF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Response Biomedical Corp (RPBIF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Response Biomedical Corp Insider Transactions

No Available Data

What does Sierra Oncology Inc do?

Who are the key executives at Sierra Oncology Inc?

Peter A. Thompson is the director of Sierra Oncology Inc. Other key executives at Sierra Oncology Inc include director & 10 percent owner Vivo Opportunity Fund Holdings, L.p. , Chief Reg & Tech Ops Officer William D. Turner , and General Counsel Mary Christina Thomson .

Sierra Oncology Inc (SRRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sierra Oncology Inc (SRRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sierra Oncology Inc (SRRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sierra Oncology Inc (SRRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sierra Oncology Inc Insider Transactions

No Available Data

What does Mirati Therapeutics Inc do?

Who are the key executives at Mirati Therapeutics Inc?

Peter A. Thompson is the director of Mirati Therapeutics Inc. Other key executives at Mirati Therapeutics Inc include EVP & Chief Commercial Officer Benjamin Hickey , Sr. Vice President & Chief Scie Jamie Christensen , and Interim CFO Aaron Ondrey .

Mirati Therapeutics Inc (MRTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Mirati Therapeutics Inc (MRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Mirati Therapeutics Inc (MRTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Mirati Therapeutics Inc (MRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirati Therapeutics Inc Insider Transactions

No Available Data

What does Anthera Pharmaceuticals Inc do?

Who are the key executives at Anthera Pharmaceuticals Inc?

Peter A. Thompson is the director of Anthera Pharmaceuticals Inc. Other key executives at Anthera Pharmaceuticals Inc include Chief Medical Officer Shanahan William R Jr , Chief Regulatory Officer Klara Dickinson , and Chief Technology Officer Charles V Olson .

Anthera Pharmaceuticals Inc (ANTH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Anthera Pharmaceuticals Inc (ANTH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Anthera Pharmaceuticals Inc (ANTH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Anthera Pharmaceuticals Inc (ANTH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Anthera Pharmaceuticals Inc Insider Transactions

No Available Data

What does Decibel Therapeutics Inc do?

Who are the key executives at Decibel Therapeutics Inc?

Peter A. Thompson is the director & 10 percent owner of Decibel Therapeutics Inc. Other key executives at Decibel Therapeutics Inc include See Remarks James B Murphy , See Remarks Anna Trask , and director & See Remarks Laurence Reid .

Decibel Therapeutics Inc (DBTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Decibel Therapeutics Inc (DBTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Decibel Therapeutics Inc (DBTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Decibel Therapeutics Inc (DBTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Decibel Therapeutics Inc Insider Transactions

No Available Data

What does Silverback Therapeutics Inc do?

Who are the key executives at Silverback Therapeutics Inc?

Peter A. Thompson is the director & 10 percent owner of Silverback Therapeutics Inc. Other key executives at Silverback Therapeutics Inc include Chief Operating Officer Brian Dorsey , Chief Legal Officer Alexander A Fitzpatrick , and director & 10 percent owner & other: * Director by deputization Deerfield Management Company, L.p. (series C) .

Silverback Therapeutics Inc (SBTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Silverback Therapeutics Inc (SBTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Silverback Therapeutics Inc (SBTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Silverback Therapeutics Inc (SBTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Silverback Therapeutics Inc Insider Transactions

No Available Data

What does Edgewise Therapeutics Inc do?

Who are the key executives at Edgewise Therapeutics Inc?

Peter A. Thompson is the director & 10 percent owner of Edgewise Therapeutics Inc. Other key executives at Edgewise Therapeutics Inc include CMO Joanne M. Donovan , Chief Financial Officer R Michael Carruthers , and General Counsel John R Moore .

Edgewise Therapeutics Inc (EWTX) Insider Trades Summary

Over the past 18 months, Peter A. Thompson made 2 insider transaction in Edgewise Therapeutics Inc (EWTX) with a net purchase of 951,316. Other recent insider transactions involving Edgewise Therapeutics Inc (EWTX) include a net sale of 187,542 shares made by Alan J Russell , a net sale of 65,477 shares made by Behrad Derakhshan , and a net sale of 218,563 shares made by R Michael Carruthers .

In summary, during the past 3 months, insiders sold 15,949 shares of Edgewise Therapeutics Inc (EWTX) in total and bought 0 shares, with a net sale of 15,949 shares. During the past 18 months, 664,029 shares of Edgewise Therapeutics Inc (EWTX) were sold and 1,902,632 shares were bought by its insiders, resulting in a net purchase of 1,238,603 shares.

Edgewise Therapeutics Inc (EWTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Edgewise Therapeutics Inc Insider Transactions

No Available Data

What does Janux Therapeutics Inc do?

Who are the key executives at Janux Therapeutics Inc?

Peter A. Thompson is the director of Janux Therapeutics Inc. Other key executives at Janux Therapeutics Inc include Chief Business Officer Andrew Hollman Meyer , director & 10 percent owner Ra Capital Healthcare Fund Lp , and director & Chief Executive Officer David Alan Campbell .

Janux Therapeutics Inc (JANX) Insider Trades Summary

Over the past 18 months, Peter A. Thompson made no insider transaction in Janux Therapeutics Inc (JANX). Other recent insider transactions involving Janux Therapeutics Inc (JANX) include a net sale of 120,000 shares made by David Alan Campbell , a net sale of 76,669 shares made by Andrew Hollman Meyer , and a net sale of 4,174,180 shares made by Avalon Ventures Xi, L.p. .

In summary, during the past 3 months, insiders sold 6,667 shares of Janux Therapeutics Inc (JANX) in total and bought 0 shares, with a net sale of 6,667 shares. During the past 18 months, 6,702,385 shares of Janux Therapeutics Inc (JANX) were sold and 2,024,041 shares were bought by its insiders, resulting in a net sale of 4,678,344 shares.

Janux Therapeutics Inc (JANX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Janux Therapeutics Inc Insider Transactions

No Available Data

What does ARS Pharmaceuticals Inc do?

Who are the key executives at ARS Pharmaceuticals Inc?

Peter A. Thompson is the director of ARS Pharmaceuticals Inc. Other key executives at ARS Pharmaceuticals Inc include Chief Commercial Officer Eric Karas , director & 10 percent owner & other: Director by deputization James E Flynn , and Chief Legal Officer Alexander A Fitzpatrick .

ARS Pharmaceuticals Inc (SPRY) Insider Trades Summary

Over the past 18 months, Peter A. Thompson made 2 insider transaction in ARS Pharmaceuticals Inc (SPRY) with a net sale of 952,377. Other recent insider transactions involving ARS Pharmaceuticals Inc (SPRY) include a net sale of 2,003,260 shares made by Sarina Tanimoto , a net sale of 2,003,260 shares made by Richard E Lowenthal , and a net sale of 70,000 shares made by Eric Karas .

In summary, during the past 3 months, insiders sold 1,043,118 shares of ARS Pharmaceuticals Inc (SPRY) in total and bought 0 shares, with a net sale of 1,043,118 shares. During the past 18 months, 8,631,909 shares of ARS Pharmaceuticals Inc (SPRY) were sold and 1,401,299 shares were bought by its insiders, resulting in a net sale of 7,230,610 shares.

ARS Pharmaceuticals Inc (SPRY)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARS Pharmaceuticals Inc Insider Transactions

No Available Data

Peter A. Thompson Mailing Address

Above is the net worth, insider trading, and ownership report for Peter A. Thompson. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Peter A. Thompson's mailing address is: Hayward Ca 94545.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.